Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wakunaga takes Japanese quinolone case to Supreme Court

This article was originally published in Scrip

Executive Summary

Wakunaga Pharmaceutical has taken its fight with fellow Japanese company Dainippon Sumitomo Pharma (DSP) to the Supreme Court. The small firm has appealed a recent Osaka High Court decision that rejected its claims against DSP in a long-running dispute over a terminated 1998 licensing deal for a quinolone antibacterial. DSP brought the High Court appeal following a 2007 district court decision ordering it to pay ¥890 million ($8.9 million) in damages to Wakunaga (scripnews.com, March 27th, 2009). Wakunaga first filed suit in 2004, claiming then that Dainippon (which merged with Sumitomo Pharma in 2005) had acted improperly.

You may also be interested in...



ASCO 2020: Positive Early Data For Keytruda/Lenvima In Liver, Kidney Cancer

Partners say they are encouraged by new overall response data from early trials for the two drugs together in kidney and liver cancer, presented to ASCO.

Deal Watch: Chinook To Go Public Via Reverse Merger With Troubled Aduro

Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.

ASCO 2020: Pevonedistat Shows Promise In Higher-Risk MDS

Takeda is confident about the promise of its first-in-class molecule for higher-risk myelodysplastic syndromes after positive Phase II data.

Topics

Related Companies

UsernamePublicRestriction

Register

AG002833

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel